Market Research Logo

Pharmaceuticals in Japan

Pharmaceuticals in Japan

Summary

Pharmaceuticals in Japan industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Japan pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key highlights

  • The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
  • The Japanese pharmaceuticals market had total revenues of $68.2bn in 2017, representing a compound annual growth rate (CAGR) of 0.2% between 2013 and 2017.
  • The greatest challenge to the Japanese pharmaceutical market is developing drugs for an aging population at a price which is acceptable to the Japanese taxpayer and government.
  • In a similar fashion to other developed countries, the government has begun a number of initiatives to control healthcare spending. Consequently there are pressures to keep a lid on health expenditure, which helps to explain slow growth over recent years.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Japan
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Japan
  • Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Japan pharmaceuticals market with five year forecasts
Reasons to buy
  • What was the size of the Japan pharmaceuticals market by value in 2017?
  • What will be the size of the Japan pharmaceuticals market in 2022?
  • What factors are affecting the strength of competition in the Japan pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitiors in Japan's pharmaceuticals market?


Executive Summary
Market value
Market value forecast
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Geography segmentation
Market share
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Astellas Pharma Inc.
Daiichi Sankyo Co Ltd
Mitsubishi Tanabe Pharma Corporation
Takeda Pharmaceutical Company Limited
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
List of Tables
Table 1: Japan pharmaceuticals market value: $ billion, 2013-17
Table 2: Japan pharmaceuticals market geography segmentation: $ billion, 2017
Table 3: Japan pharmaceuticals market share: % share, by value, 2017
Table 4: Japan pharmaceuticals market value forecast: $ billion, 2017-22
Table 5: Astellas Pharma Inc.: key facts
Table 6: Astellas Pharma Inc.: key financials ($)
Table 7: Astellas Pharma Inc.: key financials (¥)
Table 8: Astellas Pharma Inc.: key financial ratios
Table 9: Daiichi Sankyo Co Ltd: key facts
Table 10: Daiichi Sankyo Co Ltd: key financials ($)
Table 11: Daiichi Sankyo Co Ltd: key financials (¥)
Table 12: Daiichi Sankyo Co Ltd: key financial ratios
Table 13: Mitsubishi Tanabe Pharma Corporation: key facts
Table 14: Mitsubishi Tanabe Pharma Corporation: key financials ($)
Table 15: Mitsubishi Tanabe Pharma Corporation: key financials (¥)
Table 16: Mitsubishi Tanabe Pharma Corporation: key financial ratios
Table 17: Takeda Pharmaceutical Company Limited: key facts
Table 18: Takeda Pharmaceutical Company Limited: key financials ($)
Table 19: Takeda Pharmaceutical Company Limited: key financials (¥)
Table 20: Takeda Pharmaceutical Company Limited: key financial ratios
Table 21: Japan size of population (million), 2013-17
Table 22: Japan gdp (constant 2005 prices, $ billion), 2013-17
Table 23: Japan gdp (current prices, $ billion), 2013-17
Table 24: Japan inflation, 2013-17
Table 25: Japan consumer price index (absolute), 2013-17
Table 26: Japan exchange rate, 2013-17
List of Figures
Figure 1: Japan pharmaceuticals market value: $ billion, 2013-17
Figure 2: Japan pharmaceuticals market geography segmentation: % share, by value, 2017
Figure 3: Japan pharmaceuticals market share: % share, by value, 2017
Figure 4: Japan pharmaceuticals market value forecast: $ billion, 2017-22
Figure 5: Forces driving competition in the pharmaceuticals market in Japan, 2017
Figure 6: Drivers of buyer power in the pharmaceuticals market in Japan, 2017
Figure 7: Drivers of supplier power in the pharmaceuticals market in Japan, 2017
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Japan, 2017
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Japan, 2017
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Japan, 2017
Figure 11: Astellas Pharma Inc.: revenues & profitability
Figure 12: Astellas Pharma Inc.: assets & liabilities
Figure 13: Daiichi Sankyo Co Ltd: revenues & profitability
Figure 14: Daiichi Sankyo Co Ltd: assets & liabilities
Figure 15: Mitsubishi Tanabe Pharma Corporation: revenues & profitability
Figure 16: Mitsubishi Tanabe Pharma Corporation: assets & liabilities
Figure 17: Takeda Pharmaceutical Company Limited: revenues & profitability
Figure 18: Takeda Pharmaceutical Company Limited: assets & liabilities

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report